These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Residual dyslipidemia among United States adults treated with lipid modifying therapy (data from National Health and Nutrition Examination Survey 2009-2010). Wong ND; Chuang J; Wong K; Pham A; Neff D; Marrett E Am J Cardiol; 2013 Aug; 112(3):373-9. PubMed ID: 23642513 [TBL] [Abstract][Full Text] [Related]
4. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. Cziraky MJ; Watson KE; Talbert RL J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279 [TBL] [Abstract][Full Text] [Related]
5. Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs. Laforest L; Souchet T; Moulin P; Ritleng C; Desamericq G; Le Jeunne P; Schwalm MS; Van Ganse E Arch Cardiovasc Dis; 2009 Jan; 102(1):43-50. PubMed ID: 19233108 [TBL] [Abstract][Full Text] [Related]
6. [Drug therapy of dyslipidemias]. Fonda M; Cattin L; Guarnieri G Recenti Prog Med; 2000; 91(7-8):375-8. PubMed ID: 10932924 [No Abstract] [Full Text] [Related]
7. Rationale for and outline of the recommendations of the Working Group on Hypercholesterolemia and Other Dyslipidemias: interim report. Dyslipidemia Working Group of Health Canada. Frohlich J; Fodor G; McPherson R; Genest J; Langner N Can J Cardiol; 1998 Apr; 14 Suppl A():17A-21A. PubMed ID: 9594929 [TBL] [Abstract][Full Text] [Related]
9. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk. Velussi M Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):29-35. PubMed ID: 12125227 [TBL] [Abstract][Full Text] [Related]
10. Advances in the management of hyperlipidemia-induced atherosclerosis. Tannock LR Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):369-83. PubMed ID: 18327996 [TBL] [Abstract][Full Text] [Related]
11. [Lipid lowering after percutaneous coronary intervention. Intended and achieved treatment goals in real life]. Germing A; Lindstaedt M; Mügge A Med Klin (Munich); 2005 Dec; 100(12):781-4. PubMed ID: 16453092 [TBL] [Abstract][Full Text] [Related]
13. Non-adherence to lipid-lowering therapies: a need for more studies to evaluate reasons for medication non-adherence. Wong MC; Wang HH; Liu KS Int J Clin Pract; 2011 Dec; 65(12):1321-2. PubMed ID: 22093540 [No Abstract] [Full Text] [Related]
14. Niacin as a component of combination therapy for dyslipidemia. Miller M Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785 [TBL] [Abstract][Full Text] [Related]
15. Treatment of high-risk older persons with lipid-lowering drug therapy. Aronow WS Am J Ther; 2008; 15(2):102-7. PubMed ID: 18356628 [TBL] [Abstract][Full Text] [Related]
16. [Optimal lipid treatment: possibilities and current limitations]. Klose G Internist (Berl); 2011 Mar; 52(3):328-35. PubMed ID: 21331642 [TBL] [Abstract][Full Text] [Related]
17. Achieving optimal lipid goals in patients with coronary artery disease. Karalis DG; Subramanya RD; Hessen SE; Liu L; Victor MF Am J Cardiol; 2011 Mar; 107(6):886-90. PubMed ID: 21247526 [TBL] [Abstract][Full Text] [Related]
18. Lipid management with statins. The lower the better? Laufs U; Liao JK; Böhm M Z Kardiol; 2004 Jan; 93(1):4-9. PubMed ID: 14740235 [TBL] [Abstract][Full Text] [Related]
19. Cholesterol: precursor to many lipid disorders. Jones PH Am J Manag Care; 2001 Aug; 7(9 Suppl):S289-98. PubMed ID: 11517815 [TBL] [Abstract][Full Text] [Related]
20. [Hypolipidemic agents and their indication]. Teramoto T Nihon Rinsho; 2001 Mar; 59 Suppl 3():559-65. PubMed ID: 11347132 [No Abstract] [Full Text] [Related] [Next] [New Search]